-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
MediPharm Labs Q2 Revenue Declines 14% YoY, Here Are The Details
MediPharm Labs Q2 Revenue Declines 14% YoY, Here Are The Details
MediPharm Labs Corp. (OTCQX:MEDIF) (TSX:LABS) (FSE:MLZ) Q2 2022 revenue declined 14%, to CA$4.36 million ($3,37 million), compared to revenue of CA$5.07 million in Q2 2021.
Q2 2022 Financial Highlights
-
Gross profit was a loss of CA$532,000, compared to a loss of CA$7.73 million in Q2 2021.
-
Adjusted EBITDA was a loss of CA$6.34 million, compared to a loss of CA$7.43 million in Q2 2021.
Other Highlights
-
On April 20th, David Pidduck was named CEO and director of the company.
-
Subsequent to the quarter, entered into a share purchase agreement for the sale of MediPharm Labs Australia PTY for a minimum of AUD$6.9 million, which is expected to close in Q3 or Q4 2022. The company expects to save approximately CA$4M in expenses annualized following the sale of this facility.
-
Implemented a restructuring plan that will reduce Canadian non-manufacturing headcount by approximately 30%, reducing annualized expenses by approximately CA$3M beginning in Q3 2022.
-
Subsequent to the quarter, entered into a research support agreement with the Keck School of Medicine of University of Southern California to conduct a Phase 2 trial on the efficacy of THC and CBD to treat hospice-eligible patients diagnosed with dementia and experiencing agitation.
-
In July, the company was awarded a favorable summary judgment in the Ontario Court of Justice in connection with a supply agreement dispute in the amount of CA$9.8 million. This summary judgment and subsequent payment, and the conditional sale of the Australian facility, are expected to add over CA$16 million in cash to the balance sheet.
-
The company remains materially debt free and has outright ownership of its assets, including its GMP facility in Ontario.
-
Photo by Esteban Lopez on Unsplash
Related News
MediPharm Labs Awarded Payment Of CA$9.8M By Ontario Court Of Justice
MediPharm Labs Enters Into CA$4.68M Purchase Agreement For The Sale Of Australian Facility
MediPharm Labs Q1 Revenue Slightly Drops, Here Are The Details
Â
MediPharm Labs Corp. (OTCQX:MEDIF) (TSX:LABS) (FSE:MLZ) Q2 2022 revenue declined 14%, to CA$4.36 million ($3,37 million), compared to revenue of CA$5.07 million in Q2 2021.
醫療藥業實驗室公司(OTCQX:MEDIF)(多倫多證券交易所:實驗室)(FSE:MLZ)2022年第二季度收入下降14%,至436萬加元(33.7億美元),而2021年第二季度的收入為507萬加元。
Q2 2022 Financial Highlights
2022年第二季度財務亮點
-
Gross profit was a loss of CA$532,000, compared to a loss of CA$7.73 million in Q2 2021.
-
Adjusted EBITDA was a loss of CA$6.34 million, compared to a loss of CA$7.43 million in Q2 2021.
-
毛利潤虧損532,000加元,相比之下,2021年第二季度虧損773萬加元。
-
調整後的EBITDA虧損634萬加元, 相比之下,2021年第二季度虧損743萬加元。
Other Highlights
其他亮點
-
On April 20th, David Pidduck was named CEO and director of the company.
-
Subsequent to the quarter, entered into a share purchase agreement for the sale of MediPharm Labs Australia PTY for a minimum of AUD$6.9 million, which is expected to close in Q3 or Q4 2022. The company expects to save approximately CA$4M in expenses annualized following the sale of this facility.
-
Implemented a restructuring plan that will reduce Canadian non-manufacturing headcount by approximately 30%, reducing annualized expenses by approximately CA$3M beginning in Q3 2022.
-
Subsequent to the quarter, entered into a research support agreement with the Keck School of Medicine of University of Southern California to conduct a Phase 2 trial on the efficacy of THC and CBD to treat hospice-eligible patients diagnosed with dementia and experiencing agitation.
-
In July, the company was awarded a favorable summary judgment in the Ontario Court of Justice in connection with a supply agreement dispute in the amount of CA$9.8 million. This summary judgment and subsequent payment, and the conditional sale of the Australian facility, are expected to add over CA$16 million in cash to the balance sheet.
-
The company remains materially debt free and has outright ownership of its assets, including its GMP facility in Ontario.
-
Photo by Esteban Lopez on Unsplash
-
4月20日這是, 大衞·皮達克被任命為該公司首席執行官兼董事。
-
在本季度之後,就以最低6.9澳元的價格出售澳大利亞醫藥實驗室Pty百萬,預計將在2022年第三季度或第四季度關閉。該公司預計在出售這一設施後,每年將節省約400萬加元的費用。
-
實施重組計劃,將將加拿大非製造業員工人數減少約30%從2022年第三季度開始,年化支出減少約300萬加元。
-
在本季度之後,與南加州大學凱克醫學院進行第二階段試驗THC和CBD的藥效治療符合臨終關懷條件的患者,診斷為痴呆症並經歷着激動不安。
-
今年7月,該公司在安大略省法院就一起供應協議糾紛獲得了一項有利的簡易判決,金額為980萬加元。這項簡易判決和隨後的付款,以及有條件的出售澳大利亞設施,預計將使資產負債表增加1600多萬加元的現金。
-
該公司仍然基本上沒有債務,並完全擁有其資產,包括其位於安大略省的GMP設施。
-
Esteban Lopez在Unspash上的照片
Related News
相關新聞
MediPharm Labs Awarded Payment Of CA$9.8M By Ontario Court Of Justice
安大略省法院裁定MediPharm Labs支付980萬加元
MediPharm Labs Enters Into CA$4.68M Purchase Agreement For The Sale Of Australian Facility
MediPharm Labs簽署468萬加元的購買協議出售澳大利亞設施
MediPharm Labs Q1 Revenue Slightly Drops, Here Are The Details
醫藥實驗室第一季度收入略有下降,以下是詳細信息
Â
Â
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧